Executives On The Move: Five Prime Fills Its CFO Slot, Myovant Appoints Chief Commercial Officer and Onconova Adds a CMO, R&D
Executive Summary
Immuno-oncology treatment developer Five Prime Therapeutics hires a CFO, while Myovant Sciences, focused on women’s health and endocrine disease, appoints a chief commercial officer. And Onconova Therapeutics boosts its drug development expertise with addition of new CMO, R&D.
You may also be interested in...
Pipeline Watch: Six Approvals And 15 Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: Three New CMOs And CFOs Among This Week's Changes
Recent moves in the industry include C-suite shuffles at PureTech Health and Traws Pharma, plus Xencor gets a new chief financial officer.
Pipeline Watch: Six Approvals And Nine Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.